Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a rare variant of non-small cell lung cancer (NSCLC) that exhibits both epithelial and sarcomatous features. This particular subtype is known for its resistance to standard radiation treatments and its propensity for spreading. Since the ideal treatment plan for PSC with small intestinal metastasis is not yet known, evaluation of the clinical efficacy of various treatment options can be helpful for therapeutic decision-making. Methodology: A PD-L1 inhibitor called durvalumab has shown clinical promise in the management of PSC. The goal of the study was to find out how well durvalumab therapy worked in people with PSC and small intestinal metastasis after the local lesion was cut out and durvalumab was given. Participants were advised to engage in routine assessments during the course of the research study, and their progress was thereafter monitored through telephone communication. Results: During the course of therapy follow up, it was observed that patients did not exhibit substantial alternations in tumor lesion volume and did not manifest major side effects. One of the patients expired due to undetermined causes during the 11th month of the continuous follow up period. Conclusion: We proposed that surgical resection therapy combined with immunotherapy for PSC with metastasis in the small intestine can show better local control, manageable side effects, and a possible improvement in survival. This treatment modality may be a novel and successful PSC treatment; hence, future investigation is needed.